Australia New Zealand Gynaecological Oncology Group
🇦🇺Australia
- Country
- 🇦🇺Australia
- Ownership
- Private
- Established
- 2000-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://www.anzgog.org.au
Clinical Trials
4
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (100.0%)EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma
Phase 2
Recruiting
- Conditions
- Ovarian CarcinosarcomaUterine Carcinosarcoma
- Interventions
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2025-02-04
- Target Recruit Count
- 30
- Registration Number
- NCT05619913
- Locations
- 🇦🇺
Prince of Wales Hospital, Randwick, New South Wales, Australia
🇦🇺Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
🇦🇺Monash Health, Clayton, Victoria, Australia
Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy
Phase 2
Withdrawn
- Conditions
- Metastatic Cervical Cancer
- Interventions
Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy
News
No news found